Grace Therapeutics
- Biotech or pharma, therapeutic R&D
GTx-104 has reported positive Phase 3 data and gearing up for NDA submission in 2Q25. GTx-102 aligned with FDA on its next pivotal Phase 3 trial. Interest in hospital programs. Service providers N/A
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}